Cannabis in United Kingdom

The United Kingdom legalized medical cannabis in November 2018 following high-profile cases of children with severe epilepsy being denied access to cannabis-based medicines. The change was driven by public pressure after cases like those of Billy Caldwell and Alfie Dingley received widespread media attention, leading then-Home Secretary Sajid Javid to commission a review that resulted in rescheduling.

Despite legalization, NHS access to medical cannabis has been extremely limited. As of 2026, only a handful of NHS prescriptions for cannabis-based medicines have been issued, with the vast majority of medical cannabis patients obtaining prescriptions through private clinics. The private medical cannabis market has grown rapidly, with an estimated 30,000+ registered patients accessing cannabis through specialized private clinics and licensed pharmacies. Products are typically imported from licensed producers in countries including Canada, Australia, Portugal, and Denmark.

The UK has the interesting distinction of being one of the world's largest exporters of legal cannabis through GW Pharmaceuticals (now part of Jazz Pharmaceuticals), which produces Epidiolex and Sativex at facilities in the UK. British Sugar also holds a license to cultivate cannabis for GW's pharmaceutical production. This creates the paradox of the UK being a major cannabis producer and exporter while maintaining restrictive domestic access policies.

Recreational cannabis remains illegal in the UK, with possession classified as a Class B drug carrying penalties of up to five years in prison. However, enforcement varies significantly by region, and several police forces have effectively deprioritized cannabis possession for personal use. Political support for recreational legalization is growing but remains a minority position in Parliament.